Wells Fargo’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-25,093
| Closed | -$461K | – | 7755 |
|
|
2020
Q4 | $461K | Buy |
25,093
+12,113
| +93% | +$221K | ﹤0.01% | 4575 |
|
|
2020
Q3 | $239K | Sell |
12,980
-2,180
| -14% | -$36.6K | ﹤0.01% | 4866 |
|
|
2020
Q2 | $227K | Buy |
15,160
+6,017
| +66% | +$85.9K | ﹤0.01% | 4831 |
|
|
2020
Q1 | $145K | Sell |
9,143
-551
| -6% | -$8.9K | ﹤0.01% | 4874 |
|
|
2019
Q4 | $157K | Sell |
9,694
-86
| -0.9% | -$1.43K | ﹤0.01% | 5091 |
|
|
2019
Q3 | $145K | Buy |
9,780
+159
| +2% | +$2.14K | ﹤0.01% | 5146 |
|
|
2019
Q2 | $159K | Sell |
9,621
-830
| -8% | -$13.6K | ﹤0.01% | 5095 |
|
|
2019
Q1 | $181K | Buy |
10,451
+4,789
| +85% | +$86.9K | ﹤0.01% | 4876 |
|
|
2018
Q4 | $100K | Sell |
5,662
-12,284
| -68% | -$209K | ﹤0.01% | 5279 |
|
|
2018
Q3 | $326K | Buy |
17,946
+4,114
| +30% | +$84.4K | ﹤0.01% | 4732 |
|
|
2018
Q2 | $271K | Buy |
+13,832
| New | +$259K | ﹤0.01% | 4868 |
|
|
2017
Q4 | – | Sell |
-3,610
| Closed | -$38K | – | 6625 |
|
|
2017
Q3 | $38K | Buy |
+3,610
| New | +$34.2K | ﹤0.01% | 5549 |
|
|
2017
Q2 | – | Sell |
-8,779
| Closed | -$104K | – | 6558 |
|
|
2017
Q1 | $104K | Hold |
8,779
| – | – | ﹤0.01% | 5182 |
|
|
2016
Q4 | $115K | Buy |
8,779
+3,994
| +83% | +$53.5K | ﹤0.01% | 5082 |
|
|
2016
Q3 | $69K | Hold |
4,785
| – | – | ﹤0.01% | 5136 |
|
|
2016
Q2 | $57K | Sell |
4,785
-945
| -16% | -$15.2K | ﹤0.01% | 5146 |
|
|
2016
Q1 | $107K | Buy |
5,730
+887
| +18% | +$14.7K | ﹤0.01% | 4783 |
|
|
2015
Q4 | $104K | Sell |
4,843
-182
| -4% | -$3.85K | ﹤0.01% | 4886 |
|
|
2015
Q3 | $85K | Buy |
5,025
+4,532
| +919% | +$113K | ﹤0.01% | 4999 |
|
|
2015
Q2 | $18K | Buy |
493
+450
| +1,047% | +$14.5K | ﹤0.01% | 5642 |
|
|
2015
Q1 | $1K | Buy |
+43
| New | +$1.16K | ﹤0.01% | 6093 |
|
Wells Fargo's CBMG Position: Q1 2021 in Review
Wells Fargo sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 25,093 shares — an estimated $461K sold.
Wells Fargo first reported a position in CBMG in Q1 2015 and held it in 21 quarters. The position peaked at $461K in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Wells Fargo reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Wells Fargo sold 25,093 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $461K.
- Wells Fargo first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 21 quarters.
- Wells Fargo's Cellular Biomedicine Group, Inc. position peaked at $461K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Wells Fargo's 13F filing for Q1 2021, filed 13 May 2021.